A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
CD
Chai DiscoveryChai Discovery builds generative AI foundation models that predict and design protein and antibody structures to accelerate pre-clinical drug discovery.
2 Pulse stories
Total Raised
$600M
ApnimedChai Discovery
Last Valuation
$3.8B
ApnimedChai Discovery
Biotech
Sector
Biotech
2017
Founded
2024
Cambridge, Massachusetts
HQ
San Francisco, CA
Public (APMD)
Status
Private
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Chai Discovery investors
Index VenturesSequoia CapitalDimensionKleiner Perkins
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Chai Discovery.